Current understanding of insulin resistance in hepatitis C

References

• Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin. Microbiol. Infect.17, 107–115 (2011).
   PubMed Web of Science ®Google Scholar
• Alberti A, Vario A, Ferrari A, Pistis R. Review article: chronic hepatitis C – natural history and cofactors. Aliment. Pharmacol. Ther.22(Suppl. 2), 74–78 (2005).
   PubMedGoogle Scholar
• Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut55, 123–130 (2006).
   PubMed Web of Science ®Google Scholar
• Leandro G, Mangia A, Hui J et al. The relationship between hepatic steatosis, inflammation and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology130, 1636–1642 (2006).
   PubMed Web of Science ®Google Scholar
• Hui JM, Sud A, Farrell GC et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology125, 1695–1704 (2003).
   PubMed Web of Science ®Google Scholar
• Deltenre P, Louvet A, Lemoine M et al. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis. J. Hepatol. DOI: 10.1016/j.jhep.2011.03.010 (2011) (Epub ahead of print).
   Google Scholar
• Allison ME, Wreghitt T, Palmer CR, Alexander GJM. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J. Hepatol.21, 1135–1139 (1994).
   PubMed Web of Science ®Google Scholar
• Mason AL, Lau JYN, Hoang N et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology29, 328–333 (1999).
   PubMed Web of Science ®Google Scholar
• Zein NN, Abdulkarim AS, Wiesner RH et al. Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J. Hepatol.32, 209–217 (2000).
   PubMed Web of Science ®Google Scholar
• Howard AA, Klein RS, Schoenbaum EE. Association of hepatitis C infection and antiretroviral use with diabetes mellitus in drug users. Clin. Infect. Dis.36, 1318–1323 (2003).
   PubMed Web of Science ®Google Scholar
• Lecube A, Hernández C, Genescà J, Esteban JI, Jardí R, Simó R. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury. Diabetes Care27, 1171–1175 (2004).
   PubMed Web of Science ®Google Scholar
• Huang JF, Dai CY, Hwang SJ et al. Hepatitis C viremia increases the association with Type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication. Am. J. Gastroenterol.102, 1237–1243 (2007).
   PubMed Web of Science ®Google Scholar
• Imazeki F, Yokosuka O, Fukai K et al. Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients. Liver Int.28, 355–362 (2008).
   PubMed Web of Science ®Google Scholar
• Ozyilkan E, Arslan M. Increased prevalence of diabetes mellitus in patients with chronic hepatitis C virus infection. Am. J. Gastroenterol.91, 1480–1481 (1996).
   PubMed Web of Science ®Google Scholar
• Grimbert S, Valensi P, Lévy-Marchal C et al. High prevalence of diabetes mellitus in patients with chronic hepatitis C. A case–control study. Gastroenterol. Clin. Biol.20, 544–548 (1996).
   PubMedGoogle Scholar
• Caronia S, Taylor K, Pagliaro L et al. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology30, 1059–1063 (1999).
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Hampel H, Yeh C et al. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology36, 1439–1445 (2002).
   PubMed Web of Science ®Google Scholar
• Hirakauva EY, Ferraz ML, Perez RM et al. Prevalence of diabetes mellitus in renal transplant patients with hepatitis B or C virus infection. Transplant. Proc.34, 3220–3222 (2002).
   PubMedGoogle Scholar
• Antonelli A, Ferri C, Fallahi P et al. Hepatitis C virus infection: evidence for an association with Type 2 diabetes. Diabetes Care28, 2548–2550 (2005).
   PubMed Web of Science ®Google Scholar
• Huang JF, Yu ML, Dai CY et al. Reappraisal of the characteristics of glucose abnormalities in patients with chronic hepatitis C infection. Am. J. Gastroenterol.103, 1933–1940 (2008).
   PubMed Web of Science ®Google Scholar
• Zein CO, Levy C, Basu A et al. Chronic hepatitis C and Type II diabetes mellitus: a prospective cross-sectional study. Am. J. Gastroenterol.100, 48–55 (2005).
   PubMedGoogle Scholar
• Mangia A, Schiavone G, Lezzi G et al. HCV and diabetes mellitus: evidence for a negative association. Am. J. Gastroenterol.93, 2363–2367 (1998).
   PubMed Web of Science ®Google Scholar
• Gray H, Wreghitt T, Stratton IM et al. High prevalence of hepatitis C infection in Afro–Caribbean patients with Type 2 diabetes and abnormal liver function tests. Diabet. Med.12, 244–249 (1995).
   PubMedGoogle Scholar
• Sotiropoulos A, Peppas TA, Skliros E et al. Low prevalence of hepatitis C virus infection in Greek diabetic patients. Diabet. Med.16, 250–252 (1999).
   PubMedGoogle Scholar
• Sangiorgio L, Attardo T, Gangemi R et al. Increased frequency of HCV and HBV infection in Type 2 diabetic patients. Diabetes Res. Clin. Pract.48, 147–151 (2000).
   PubMed Web of Science ®Google Scholar
• Okan V, Araz M, Aktaran S et al. Increased frequency of HCV but not HBV infection in Type 2 diabetic patients in Turkey. Int. J. Clin. Pract.56, 175–177 (2002).
   PubMed Web of Science ®Google Scholar
• Fukui M, Kitagawa Y, Nakamura N et al. Hepatitis C virus and atherosclerosis in patients with Type 2 diabetes. JAMA289, 1245–1246 (2003).
   PubMed Web of Science ®Google Scholar
• Balogun WO, Adeleye JO, Akinlade KS et al. Low prevalence of hepatitis-C viral seropositivity among patients with Type-2 diabetes mellitus in a tertiary hospital. J. Natl Med. Assoc.98, 1805–1808 (2006).
   PubMed Web of Science ®Google Scholar
• Chen HF, Li CY, Chen P et al. Seroprevalence of hepatitis B and C in Type 2 diabetic patients. J. Chin. Med. Assoc.69, 146–152 (2006).
   PubMedGoogle Scholar
• Gulcan A, Gulcan E, Toker A et al. Evaluation of risk factors and seroprevalence of hepatitis B and C in diabetic patients in Kutahya, Turkey. J. Investig. Med.56, 858–863 (2008).
   PubMedGoogle Scholar
• Rudoni S, Petit JM, Bour JB et al. HCV infection and diabetes mellitus: influence of the use of finger stick devices on nosocomial transmission. Diabetes Metab.25, 502–505 (1999).
   PubMed Web of Science ®Google Scholar
• Mehta SH, Brancati FL, Sulkowski MS et al. Prevalence of Type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann. Intern. Med.133, 592–599 (2000).
   PubMed Web of Science ®Google Scholar
• Mehta SH, Brancati FL, Strathdee SA et al. Hepatitis C virus infection and incident Type 2 diabetes. Hepatology38, 50–56 (2003).
   PubMed Web of Science ®Google Scholar
• Wang CS, Wang ST, Yao WJ et al. Hepatitis C virus infection and the development of Type 2 diabetes in a community-based longitudinal study. Am. J. Epidemiol.166, 196–203 (2007).
   PubMed Web of Science ®Google Scholar
• White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: A systematic review and meta-analysis. J. Hepatol.49, 831–844 (2008).
   PubMed Web of Science ®Google Scholar
• Chen T, Jia H, Li J et al. New onset diabetes mellitus after liver transplantation and hepatitis C virus infection: meta-analysis of clinical studies. Transpl. Int.22, 408–415 (2009).
   PubMedGoogle Scholar
• Fabrizi F, Messa P, Martin P et al. Hepatitis C virus infection and post-transplant diabetes mellitus among renal transplant patients: a meta-analysis. Int. J. Artif. Organs31, 675–682 (2008).
   PubMed Web of Science ®Google Scholar
• Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: A metabolic pathway to chronic liver disease. Hepatology42, 987–1000 (2005).
   PubMed Web of Science ®Google Scholar
• Moucari R, Asselah T, Cazals-Hatem D et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology134, 416–423 (2008).
   PubMed Web of Science ®Google Scholar
• Tsochatzis E, Papatheodoridis GV, Hadziyannis E et al. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Scand. J. Gastroenterol.43, 1128–1136 (2008).
   PubMed Web of Science ®Google Scholar
• Muzzi A, Rubbia-Brandt L, Leandro G et al. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J. Hepatol.42, 39–44 (2005).
   Google Scholar
• Fattovich G, Covolo L, Bibert S et al.IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment. Pharm. Ther.33(10), 1162–1172 (2011).
   PubMed Web of Science ®Google Scholar
• Harrison SA. Correlation between insulin resistance and hepatitis C viral load. Hepatology43, 1168 (2006).
   PubMedGoogle Scholar
• Hsu CS, Liu CJ, Liu CH et al. High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver Int.28, 271–277 (2008).
   PubMed Web of Science ®Google Scholar
• Yoneda M, Saito S, Ikeda T et al. Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients. J. Viral Hepat.14, 600–607 (2007).
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Chand N, Comar K et al. Hyperinsulinemia blocks the inhibition of hepatitis C virus (HCV) replication by interferon: a potential mechanism for failure of interferon therapy in subjects with HCV and nonalcoholic fatty liver disease. Hepatology40(Suppl. 1), 179A (2004).
   Google Scholar
• Akuta N, Suzuki F, Hirakawa M et al. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus. J. Med. Virol.81, 1032–1039 (2009).
   PubMed Web of Science ®Google Scholar
• Sumida Y, Kanemasa K, Hara T et al. Impact of amino acid substitutions in hepatitis C virus genotype 1b core region on liver steatosis and glucose tolerance in non-cirrhotic patients without overt diabetes. J. Gastroenterol. Hepatol.26, 836–842 (2011).
   PubMedGoogle Scholar
• Kawaguchi T, Ide T, Taniguchi E et al. Clearance of HCV improves insulin resistance, β-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am. J. Gastroenterol.102, 570–576 (2007).
   PubMed Web of Science ®Google Scholar
• Chehadeh W, Abdella N, Ben-Nakhi A et al. Risk factors for the development of diabetes mellitus in chronic hepatitis C virus genotype 4 infection. J. Gastroenterol. Hepatol.24, 42–48 (2009).
   PubMed Web of Science ®Google Scholar
• Romero-Gómez M, Fernández-Rodríguez CM, Andrade RJ et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J. Hepatol.48, 721–727 (2008).
   PubMed Web of Science ®Google Scholar
• Arase Y, Suzuki F, Suzuki Y et al. Sustained virological response reduces incidence of onset of Type 2 diabetes in chronic hepatitis C. Hepatology49, 739–744 (2009).
   PubMed Web of Science ®Google Scholar
• Simó R, Lecube A, Genescà J et al. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care29, 2462–2466 (2006).
   PubMed Web of Science ®Google Scholar
• Giordanino C, Bugianesi E, Smedile A et al. Incidence of Type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study. Am. J. Gastroenterol.103, 2481–2487 (2008).
   PubMed Web of Science ®Google Scholar
• Moucari R, Forestier N, Larrey D et al. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in genotype 1 chronic hepatitis C patients. Gut59, 1694–1698 (2010).
   PubMedGoogle Scholar
• Delgado-Borrego A, Jordan SH, Negre B et al. Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial. Clin. Gastroenterol. Hepatol.8, 458–462 (2010).
   PubMed Web of Science ®Google Scholar
• Platanias LC, Uddin S, Yetter A et al. The type I interferon receptor mediates tyrosine phosphorylation of insulin receptor substrate 2. J. Biol. Chem.271, 278–282 (1996).
   PubMed Web of Science ®Google Scholar
• Vanni E, Abate ML, Gentilcore E et al. Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology50, 697–706 (2009).
   PubMed Web of Science ®Google Scholar
• Milner KL, van der Poorten D, Trenell M et al. Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology138, 932–941, E931–E933 (2010).
   PubMed Web of Science ®Google Scholar
• Aytug S, Reich D, Sapiro LE et al. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of Type 2 diabetes. Hepatology38, 1384–1392 (2003).
   PubMed Web of Science ®Google Scholar
• Shintani Y, Fujie H, Miyoshi H et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology126, 840–848 (2004).
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Yoshida T, Harada M et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am. J. Pathol.165, 1499–1508 (2004).
   PubMed Web of Science ®Google Scholar
• Pazienza V, Clément S, Pugnale P et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology45, 1164–1171 (2007).
   PubMed Web of Science ®Google Scholar
• Howard JK, Flier JS. Attenuation of leptin and insulin signaling by SOCS proteins. Trends Endocrinol. Metab.17, 365–371 (2006).
   PubMed Web of Science ®Google Scholar
• Pascarella S, Clément S, Guilloux K et al. Effects of hepatitis C virus on suppressor of cytokine signaling mRNA levels: comparison between different genotypes and core protein sequence analysis. J. Med. Virol. (2011) (In Press).
   PubMedGoogle Scholar
• Huang J, Manning BD. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem. Soc. Trans.37, 217–222 (2009).
   PubMed Web of Science ®Google Scholar
• Gual P, Le Marchand-Brustel Y, Tanti JF. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie87, 99–109 (2005).
   PubMed Web of Science ®Google Scholar
• Banerjee S, Saito K, Ait-Goughoulte M et al. Hepatitis C virus core protein upregulates serine phosphorylation substrate-1 and impairs the downstream Akt/protein kinase B signaling pathway for insulin resistance. J. Virol.82, 2606–2612 (2008).
   PubMed Web of Science ®Google Scholar
• Garcia-Monzon C, Lo Iacono O, Mayoral R et al. Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C. J. Hepatol.54, 142–152 (2011).
   PubMed Web of Science ®Google Scholar
• Bernsmeier C, Duong FH, Christen V et al. Virus-induced over-expression of protein phosphatase 2A inhibits insulin signaling in chronic hepatitis C. J. Hepatol.49, 429–440 (2008).
   PubMed Web of Science ®Google Scholar
• Duong FH, Christen V, Berke JM et al. Upregulation of protein phosphatise 2Ac by hepatitis C virus modulates NS3 helicase activity through inhibition of protein arginine methyltransferase 1. J. Virol.79, 15342–15350 (2005).
   PubMedGoogle Scholar
• Duong FH, Filipowicz M, Tripodi M et al. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology126, 263–277 (2004).
   PubMedGoogle Scholar
• Christen V, Treves S, Duong FH et al. Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2A. Hepatology46, 558–565 (2007).
   PubMed Web of Science ®Google Scholar
• Liberman E, Fong YL, Selby MJ et al. Activation of the grp78 and grp94 promoters by hepatitis C virus E2 envelope protein. J. Virol.73, 3718–3722 (1999).
   PubMed Web of Science ®Google Scholar
• Waris G, Tardif KD, Siddiqui A. Endoplasmic reticulum (ER) stress: hepatitis C virus induces an ER-nucleus signal transduction pathway and activates NF-κB and STAT-3. Biochem. Pharmacol.64, 1425–1430 (2002).
   PubMed Web of Science ®Google Scholar
• Li S, Ye L, Yu X et al. Hepatitis C virus NS4B induces unfolded protein response and endoplasmic reticulum overload response-dependent NF-κB activation. Virology391, 257–264 (2009).
   PubMed Web of Science ®Google Scholar
• von dem Bussche A, Machida R, Li K et al. Hepatitis C virus NS2 protein triggers endoplasmic reticulum stress and suppresses its own viral replication. J. Hepatol.53, 797–804 (2010).
   PubMedGoogle Scholar
• Gowans EJ. Distribution of markers of hepatitis C virus infection throughout the body. Semin. Liver Dis.20, 85–102 (2000).
   PubMed Web of Science ®Google Scholar
• Miyamoto H, Moriishi K, Moriya K et al. Involvement of the PA28γ-dependent pathway in insulin resistance induced by hepatitis C virus core protein. J. Virol.81, 1727–1735 (2007).
   PubMed Web of Science ®Google Scholar
• Virkamaki A, Ueki K, Kahn CR. Protein–protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J. Clin. Invest.103, 931–943 (1999).
   PubMed Web of Science ®Google Scholar
• Zylberberg H, Rimaniol AC, Pol S et al. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J. Hepatol.30, 185–191 (1999).
   PubMed Web of Science ®Google Scholar
• Crespo J, Rivero M, Fabrega E et al. Plasma leptin and TNF-α levels in chronic hepatitis C patients and their relationship to hepatic fibrosis. Dig. Dis. Sci.47, 1604–1610 (2002).
   PubMed Web of Science ®Google Scholar
• Knobler H, Zhornicky T, Sandler A et al. Tumor necrosis factor-α-induced insulin resistance may mediate the hepatitis C virus-diabetes association. Am. J. Gastroenterol.98, 2751–2756 (2003).
   PubMed Web of Science ®Google Scholar
• Lecube A, Hernandez C, Genesca J et al. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: a case–control study. Diabetes Care29, 1096–1101 (2006).
   PubMed Web of Science ®Google Scholar
• Cua IH, Hui JM, Bandara P et al. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology46, 66–73 (2007).
   PubMed Web of Science ®Google Scholar
• Straczkowski M, Dzienis-Straczkowska S, Stepien A et al. Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor-α system. J. Clin. Endocrinol. Metab.87, 4602–4606 (2002).
   PubMed Web of Science ®Google Scholar
• Kim CS, Park HS, Kawada T et al. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int. J. Obes.30, 1347–1355 (2006).
   PubMed Web of Science ®Google Scholar
• Neels JG, Badeanlou L, Hester KD et al. Keratinocyte-derived chemokine in obesity: expression, regulation, and role in adipose macrophage infiltration and glucose homeostasis. J. Biol. Chem.284, 20692–20698 (2009).
   PubMedGoogle Scholar
• Kobashi C, Asamizu S, Ishiki M et al. Inhibitory effect of IL-8 on insulin action in human adipocytes via MAP kinase pathway. J. Inflamm.6, 25 (2009).
   Google Scholar
• Thorand B, Kolb H, Baumert J et al. Elevated levels of interleukin-18 predict the development of Type 2 diabetes: results from the MONICA/KORA Augsburg Study, 1984–2002. Diabetes54, 2932–2938 (2005).
   PubMed Web of Science ®Google Scholar
• Kukla M, Zwirska-Korczala K, Gabriel A et al. Chemerin, vaspin and insulin resistance in chronic hepatitis C. J. Viral. Hepat.17, 661–667 (2009).
   PubMedGoogle Scholar
• Kralisch S, Weise S, Sommer G et al. Interleukin-1β induces the novel adipokine chemerin in adipocytes in vitro. Regul. Pept.154, 102–106 (2009).
   PubMed Web of Science ®Google Scholar
• Sell H, Laurencikiene J, Taube A et al. Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes58, 2731–2740 (2009).
   PubMed Web of Science ®Google Scholar
• Becker M, Rabe K, Lebherz C et al. Expression of human chemerin induces insulin resistance in the skeletal muscle but does not affect weight, lipid levels, and atherosclerosis in LDL receptor knockout mice on high-fat diet. Diabetes59, 2898–2903 (2010).
   PubMed Web of Science ®Google Scholar
• Ratziu V, Munteanu M, Charlotte F et al. Fibrogenic impact of high serum glucose in chronic hepatitis C. J. Hepatol.39, 1049–1055 (2003).
   PubMed Web of Science ®Google Scholar
• Hickman IJ, Powell EE, Prins JB et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J. Hepatol.39, 1042–1048 (2003).
   PubMed Web of Science ®Google Scholar
• D’Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am. J. Gastroenterol.100, 1509–1515 (2005).
   PubMed Web of Science ®Google Scholar
• Bugianesi E, Marchesini G, Gentilcore E et al. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: role of insulin resistance and hepatic steatosis. Hepatology44, 1648–1655 (2006).
   PubMed Web of Science ®Google Scholar
• Kita Y, Mizukoshi E, Takamura T et al. Impact of diabetes mellitus on prognosis of patients infected with hepatitis C virus. Metabolism56, 1682–1688 (2007).
   PubMedGoogle Scholar
• Cua IHY, Hui JM, Kench JG et al. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology48, 723–731 (2008).
   PubMed Web of Science ®Google Scholar
• Foxton MR, Quaglia A, Muiesan P et al. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am. J. Transplant.6, 1922–1929 (2006).
   PubMed Web of Science ®Google Scholar
• Cotler SJ, Kallwitz E, TenCate V et al. Diabetes and hepatic oxidative damage are associated with hepatitis C progression after liver transplantation. Transplantation84, 587–591 (2007).
   PubMedGoogle Scholar
• Abbott KC, Lentine KL, Bucci JR et al. Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C virus. J. Am. Soc. Nephrol.15, 3166–3174 (2004).
   PubMedGoogle Scholar
• Paradis V, Perlemuter G, Bonvoust F et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology34, 738–744 (2001).
   PubMed Web of Science ®Google Scholar
• Hora C, Negro F, Leandro G et al. Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis C. Liver Int.28, 370–376 (2008).
   PubMed Web of Science ®Google Scholar
• Hickman IJ, Clouston AD, Macdonald GA et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut51, 89–94 (2002).
   PubMed Web of Science ®Google Scholar
• Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu. Rev. Pathol.6, 425–456 (2011).
   PubMed Web of Science ®Google Scholar
• Heydtmann M, Adams DH. Chemokines in the immunopathogenesis of hepatitis C infection. Hepatology49, 676–688 (2009).
   PubMed Web of Science ®Google Scholar
• Casini A, Ceni E, Salzano R et al. Neutrophil-derived superoxide anion induces lipid peroxidation and stimulates collagen synthesis in human hepatic stellate cells: role of nitric oxide. Hepatology25, 361–367 (1997).
   PubMed Web of Science ®Google Scholar
• Cua IH, Hui JM, Bandara P et al. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology46, 66–73 (2007).
   PubMed Web of Science ®Google Scholar
• Gwak GY, Kim TH, Yu SJ et al. Lack of association between serum leptin levels and hepatic steatosis, fibrosis or response to antiviral therapy in Korean chronic hepatitis C patients. Hepatogastroenterology54, 844–848 (2007).
   PubMedGoogle Scholar
• Myers RP, Messous D, Poynard T et al. Association between leptin, metabolic factors and liver histology in patients with chronic hepatitis C. Can. J. Gastroenterol.21, 289–294 (2007).
   PubMedGoogle Scholar
• Lo Iacono O, Venezia G, Petta S et al. The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Aliment. Pharmacol. Ther.25, 1181–1191 (2007).
   PubMed Web of Science ®Google Scholar
• Piche T, Vandenbos F, Abakar-Mahamat A et al. The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C. J. Viral. Hepat.11, 91–96 (2004).
   PubMedGoogle Scholar
• Tsochatzis E, Papatheodoridis GV, Hadziyannis E et al. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Scand. J. Gastroenterol.43, 1128–1136 (2008).
   PubMed Web of Science ®Google Scholar
• Di Martino V, Lebray P, Myers RP et al. Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology40, 1426–1433 (2004).
   PubMed Web of Science ®Google Scholar
• Codes L, Asselah T, Cazals-Hatem D et al. Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy. Gut56, 390–395 (2007).
   PubMed Web of Science ®Google Scholar
• Villa E, Karampatou A, Cammà C et al. Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. Gastroenterology140, 818–829 (2011).
   PubMed Web of Science ®Google Scholar
• Lecube A, Hernández C, Simó R. Glucose abnormalities in non-alcoholic fatty liver disease and chronic hepatitis C virus infection: the role of iron overload. Diabetes Metab. Res. Rev.25, 403–410 (2009).
   PubMedGoogle Scholar
• Walsh MJ, Vanags DM, Clouston AD et al. Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. Hepatology39, 1230–1238 (2004).
   PubMed Web of Science ®Google Scholar
• Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br. J. Cancer97, 1005–1008 (2007).
   PubMed Web of Science ®Google Scholar
• Davila JA, Morgan RO, Shaib Y et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut54, 533–539 (2005).
   PubMed Web of Science ®Google Scholar
• Nkontchou G, Bastard JP, Ziol M et al. Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis. J. Hepatol.53, 827–833 (2010).
   PubMedGoogle Scholar
• Negro F. Abnormalities of lipid metabolism in hepatitis C virus infection. Gut59, 1279–1287 (2010).
   PubMed Web of Science ®Google Scholar
• Serfaty L, Andreani T, Giral P et al. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J. Hepatol.34, 428–434 (2001).
   PubMed Web of Science ®Google Scholar
• Hofer H, Bankl HC, Wrba F et al. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am. J. Gastroenterol.97, 2880–2885 (2002).
   PubMed Web of Science ®Google Scholar
• Corey KE, Kane E, Munroe C et al. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology50, 1030–1037 (2009).
   PubMed Web of Science ®Google Scholar
• Völzke H, Schwahn C, Wolff B et al. Hepatitis B and C virus infection and the risk of atherosclerosis in a general population. Atherosclerosis174, 99–103 (2004).
   PubMed Web of Science ®Google Scholar
• Mostafa A, Mohamed MK, Saeed M et al. Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. Gut59, 1135–1140 (2010).
   PubMed Web of Science ®Google Scholar
• Targher G, Bertolini L, Padovani R et al. Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J. Hepatol.46, 1126–1132 (2007).
   PubMed Web of Science ®Google Scholar
• Demirci MS, Toz H, Yilmaz F et al. Risk factors and consequences of post-transplant diabetes mellitus. Clin. Transplant.24, E170–E177 (2010).
   Google Scholar
• Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut59, 1410–1415 (2010).
   PubMed Web of Science ®Google Scholar
• Romero-Gómez M, Del Mar Viloria M, Andrade RJ et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology128, 636–641 (2005).
   PubMed Web of Science ®Google Scholar
• Poustchi H, Negro F, Hui J et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J. Hepatol.48, 28–34 (2008).
   PubMed Web of Science ®Google Scholar
• Moucari R, Ripault MP, Martinot-Peignoux M et al. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut58, 1662–1669 (2009).
   PubMed Web of Science ®Google Scholar
• Dai CY, Huang JF, Hsieh MY et al. Insulin resistance predicts response to peginterferon-α/ribavirin combination therapy in chronic hepatitis C patients. J. Hepatol.50, 712–718 (2009).
   PubMed Web of Science ®Google Scholar
• Chu CJ, Lee SD, Hung TH et al. Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon α-2b plus ribavirin. Aliment. Pharmacol. Ther.29, 46–54 (2009).
   PubMedGoogle Scholar
• Mizuta T, Kawaguchi Y, Eguchi Y et al. Whole-body insulin sensitivity index is a highly specific predictive marker for virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients with genotype 1b and high viral load. Dig. Dis. Sci.55, 183–189 (2010).
   PubMed Web of Science ®Google Scholar
• Khattab M, Eslam M, Sharwae MA et al. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am. J. Gastroenterol.105, 1970–1977 (2010).
   PubMed Web of Science ®Google Scholar
• Conjeevaram HS, Kleiner DE, Everhart JE et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology45, 80–87 (2007).
   PubMed Web of Science ®Google Scholar
• Cacoub P, Carrat F, Bédossa P et al. Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV-hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study. Antivir. Ther.14, 839–845 (2009).
   PubMedGoogle Scholar
• Ryan P, Resino S, Miralles P et al. Insulin resistance impairs response to interferon plus ribavirin in patients coinfected with HIV and hepatitis C virus. J. Acquir. Immune Defic. Syndr.55, 176–181 (2010).
   PubMedGoogle Scholar
• Nasta P, Gatti F, Puoti M et al. Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-α-2a. AIDS22, 857–861 (2008).
   PubMed Web of Science ®Google Scholar
• Bongiovanni M, Ranieri R, Casana M et al. Insulin resistance affects early virologic response in HIV-infected subjects treated for hepatitis C infection. J. Acquir. Immune Defic. Syndr.47, 258–259 (2008).
   PubMedGoogle Scholar
• Grasso A, Malfatti F, De Leo P et al. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon α-2b plus ribavirin. J. Hepatol.51, 984–990 (2009).
   PubMedGoogle Scholar
• Neumann AU, Bain VG, Yoshida EM et al. Early prediction of sustained virological response at day 3 of treatment with albinterferon-α-2b in patients with genotype 2/3 chronic hepatitis C. Liver Int.29, 1350–1355 (2009).
   PubMedGoogle Scholar
• Durante-Mangoni E, Zampino R, Portella G et al. Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment. Clin. Infect. Dis.49, 498–506 (2009).
   PubMedGoogle Scholar
• Bortoletto G, Scribano L, Realdon S et al. Hyperinsulinaemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance. J. Viral Hepat.17, 475–480 (2010).
   PubMedGoogle Scholar
• Angelico F, Francioso S, Del Ben M et al. Clinical trial: low plasma cholesterol and oxidative stress predict rapid virological response to standard therapy with peginterferon and ribavirin in HCV patients. Aliment. Pharmacol. Ther.30, 444–451 (2009).
   PubMedGoogle Scholar
• Merchante N, de los Santos-Gil I, Merino D et al. Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients. J. Hepatol.50, 684–692 (2009).
   PubMedGoogle Scholar
• Prati GM, Rumi MG, Aghemo A et al. Insulin resistance does not predict a response to pegylated interferon plus ribavirin in chronic hepatitis C patients: a sub-analysis of the MIST study. J. Hepatol.52(Suppl. 1), S122 (2010).
   Google Scholar
• Fattovich G, Svegliati Baroni G, Leandro G et al. Post-load insulin resistance is not a predictor of sustained virologic response in chronic hepatitis C patients. Hepatology52(Suppl.), 802A (2010).
   Google Scholar
• Persico M, Capasso M, Persico E et al. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: insulin resistance and response to antiviral therapy. Hepatology46, 1009–1015 (2007).
   PubMed Web of Science ®Google Scholar
• Walsh MJ, Jonsson JR, Richardson MM et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut55, 529–535 (2006).
   PubMed Web of Science ®Google Scholar
• Gadina M, Hilton D, Johnston JA et al. Signaling by Type I and II cytokine receptors: ten years after. Curr. Opin. Immunol.13, 363–373 (2001).
   PubMed Web of Science ®Google Scholar
• Hickman IJ, Clouston AD, Macdonald GA et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut51, 89–94 (2002).
   PubMed Web of Science ®Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med.346, 393–403 (2002).
   PubMed Web of Science ®Google Scholar
• Orchard TJ, Temprosa M, Goldberg R et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann. Intern. Med.142, 611–619 (2005).
   PubMed Web of Science ®Google Scholar
• Alexander J, Tung BY, Croghan A et al. Effect of iron depletion on serum markers of fibrogenesis, oxidative stress and serum liver enzymes in chronic hepatitis C: results of a pilot study. Liver Int.27, 268–273 (2007).
   PubMedGoogle Scholar
• Kato J, Miyanishi K, Kobune M et al. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J. Gastroenterol.42, 830–836 (2007).
   PubMed Web of Science ®Google Scholar
• Donadon V, Balbi M, Ghersetti M et al. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J. Gastroenterol.15, 2506–2511 (2009).
   PubMed Web of Science ®Google Scholar
• Donadon V, Balbi M, Mas MD et al. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int.30, 750–758 (2010).
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Taniguchi E, Morita Y et al. Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection. Liver Int.30, 479–486 (2010).
   PubMed Web of Science ®Google Scholar
• Overbeck K, Genné D, Golay A et al. Pioglitazone in chronic hepatitis C not responding to pegylated interferon-α and ribavirin. J. Hepatol.49, 295–298 (2008).
   PubMed Web of Science ®Google Scholar
• Elgouhari HM, Cesario KB, Lopez R et al. Pioglitazone improves early virologic kinetic response to PEG IFN/RBV combination therapy in hepatitis C genotype 1 naive pts. Hepatology48(Suppl.), 383A (2008).
   Web of Science ®Google Scholar
• Conjeevaram H, Burant CF, McKenna et al. A randomized, double-blind, placebo-controlled study of PPAR-γ agonist pioglitazone given in combination with peginterferon and ribavirin in patients with genotype-1 chronic hepatitis C. Hepatology48(Suppl.), 384A (2008).
   Google Scholar
• Harrison SF, Hamzeh M, Lentz E et al. Virologic and metabolic responses in chronic hepatitis C (CHC) patients with insulin resistance (IR) treated with pioglitazone and peginterferon α-2a plus ribavirin. J. Hepatol.5, S129 (2010).
   Google Scholar
• Romero-Gómez M, Diago M, Andrade RJ et al. Treatment of insulin resistance with metformin in naive genotype 1 chronic hepatitis C patients receiving peginterferon α-2a plus ribavirin. Hepatology50, 1702–1708 (2009).
   PubMed Web of Science ®Google Scholar
• Khattab M, Emad M, Abdelaleem A et al. Pioglitazone improves virological response to peginterferon α-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int.30, 447–454 (2010).
   PubMed Web of Science ®Google Scholar